Literature DB >> 21727058

Effects of cyclosporine on pruritus and serum IL-31 levels in patients with atopic dermatitis.

Atsushi Otsuka, Miki Tanioka, Yujin Nakagawa, Tetsuya Honda, Akihiko Ikoma, Yoshiki Miyachi, Kenji Kabashima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21727058     DOI： 10.1684/ejd.2011.1470

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  10 in total

1.  Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.

Authors:  Saakshi Khattri; Avner Shemer; Mariya Rozenblit; Nikhil Dhingra; Tali Czarnowicki; Robert Finney; Patricia Gilleaudeau; Mary Sullivan-Whalen; Xiuzhong Zheng; Hui Xu; Irma Cardinale; Cristina de Guzman Strong; Juana Gonzalez; Mayte Suárez-Fariñas; Jim G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2014-04-29       Impact factor: 10.793

2.  Itch Relief in Atopic Dermatitis: Comparison of Narrowband Ultraviolet B Radiation and Cyclosporine Treatment.

Authors:  Andrzej Jaworek; Krystyna Szafraniec; Magdalena Jaworek; Łukasz Matusiak; Anna Wojas-Pelc; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2020-10-14       Impact factor: 3.875

Review 3.  The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus.

Authors:  Pawinee Rerknimitr; Atsushi Otsuka; Chisa Nakashima; Kenji Kabashima
Journal:  Inflamm Regen       Date:  2017-06-05

4.  The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins.

Authors:  Patrick M Brunner; Mayte Suárez-Fariñas; Helen He; Kunal Malik; Huei-Chi Wen; Juana Gonzalez; Tom Chih-Chieh Chan; Yeriel Estrada; Xiuzhong Zheng; Saakshi Khattri; Annunziata Dattola; James G Krueger; Emma Guttman-Yassky
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

Review 5.  Pruritus in Autoimmune and Inflammatory Dermatoses.

Authors:  Claudia Zeidler; Manuel Pedro Pereira; Flavien Huet; Laurent Misery; Kerstin Steinbrink; Sonja Ständer
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

Review 6.  The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo.

Authors:  Claudia Zeidler; Manuel Pereira; Sonja Ständer
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-11

Review 7.  Interleukin-31 as a Clinical Target for Pruritus Treatment.

Authors:  Kenji Kabashima; Hiroyuki Irie
Journal:  Front Med (Lausanne)       Date:  2021-02-12

Review 8.  Daily Lifestyle and Inflammatory Skin Diseases.

Authors:  Yu Sawada; Natsuko Saito-Sasaki; Emi Mashima; Motonobu Nakamura
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

Review 9.  Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics.

Authors:  Yasaman Mansouri; Emma Guttman-Yassky
Journal:  J Clin Med       Date:  2015-04-29       Impact factor: 4.241

10.  Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.

Authors:  K Kabashima; T Matsumura; H Komazaki; M Kawashima
Journal:  Br J Dermatol       Date:  2021-12-21       Impact factor: 11.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.